C-L Case Conference: Torsades de Pointes in a Patient With Lifelong Medical Trauma, COVID-19, Remdesivir, Citalopram, Quetiapine, and Hemodialysis

J Acad Consult Liaison Psychiatry. 2023 Mar-Apr;64(2):147-157. doi: 10.1016/j.jaclp.2022.11.001. Epub 2022 Nov 6.

Abstract

We present a case of Torsades de Pointes (TdP) in a patient with COVID-19 infection and multiple TdP risk factors including QT-interval prolongation, hemodialysis, bradycardia, and treatment with remdesivir, citalopram, and quetiapine. The case was complicated by post-resuscitation anxiety superimposed on a history of medical trauma since childhood. Top experts in the field of consultation-liaison psychiatry, trauma informed care, and cardiac electrophysiology provide perspectives on this case with a review of the literature. Key teaching topics include identification of TdP risk factors in patients with a complex illness; the necessity for prompt electrophysiology consultation in clinical scenarios with high risk for TdP; and the approach to patients with medical trauma using a trauma-informed lens. We highlight the contributions of COVID-19, the pharmacokinetics of QT-interval-prolonging psychotropic medications, the risks of hemodialysis, and the role of remdesivir-induced bradycardia in this first reported case of TdP in a patient treated with remdesivir.

Keywords: COVID-19; Torsades de Pointes; citalopram; hemodialysis; quetiapine; remdesivir.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Bradycardia / chemically induced
  • Bradycardia / drug therapy
  • COVID-19 Drug Treatment
  • COVID-19*
  • Child
  • Citalopram / adverse effects
  • DNA-Binding Proteins / therapeutic use
  • Humans
  • Long QT Syndrome* / chemically induced
  • Long QT Syndrome* / drug therapy
  • Quetiapine Fumarate / adverse effects
  • Renal Dialysis
  • Torsades de Pointes* / chemically induced
  • Torsades de Pointes* / drug therapy

Substances

  • Citalopram
  • Quetiapine Fumarate
  • remdesivir
  • DNA-Binding Proteins